<DOC>
	<DOCNO>NCT00873327</DOCNO>
	<brief_summary>This phase I open label multi-dose study investigate pharmacokinetics safety piperacillin-tazobactam infant &lt; 61 day age suspect sepsis . There four cohort 8 infant : 1 . &lt; 32 week gestational age ( GA ) &lt; 14 day postnatal age ( PNA ) 2 . &lt; 32 week gestational age &gt; =14 day postnatal age 3 . &gt; =32 week gestational age &lt; 14 day postnatal age 4 . &gt; =32 week gestational age &gt; =14 day postnatal age . The study require administration 6 dos study drug along antimicrobial per standard care follow 1 week safety monitoring . Four 200 µL pK sample obtain steady state . The risk reasonable vs. benefit minimize appropriately . There may benefit subject ( administration broad spectrum empirical antimicrobial therapy ) , information study may benefit large number infant drug currently administer despite lack PK data population .</brief_summary>
	<brief_title>Pharmacokinetics Safety Piperacillin-tazobactam Neonates</brief_title>
	<detailed_description>Procedures Prior Receipt First Dose Study Drug Parental/Guardian Permission Prior start study-related procedure , sign date informed consent HIPAA authorization must obtain document infant 's medical record . Once determined infant meet inclusion criterion exclusion criterion , infant assign subject identification number use subject 's CRFs consider enrol . Study Drug Administration Assignment Therapy Groups Infants meeting eligibility receive piperacillin-tazobactam . Concomitant use aminoglycoside suggest . Enrollment study drug dose stratify GA PNA . After enrollment information eligible infant provide , dosage assignment subject number allocate . If infant assign study drug number , receive study drug , subject number use . The reason dose subject note case report form ( CRF ) . Dosing : Infants &lt; 32 week gestation birth &lt; 14 day PNA 100 mg/kg Q8 &gt; =14 week PNA 100 mg/kg Q6 Infants ≥32 week gestation birth &lt; 14 day PNA 100 mg/kg Q6 &gt; =14 day PNA 100 mg/kg Q6 Dispensing Study Drug The pharmacist site prepare dispense study drug . Study drug dispense pharmacy appropriate size syrinx administer via syringe pump rate calculate base infant ' body weight kilogram ( kg ) per local standard care , target infuse product 30 minute . Immediately follow study drug administration infusion tube flush per unit protocol . Piperacillin-tazobactam mixed physically added solution contain drug . Infusion vial piperacillin-tazobactam reconstitute stored per package insert local pharmacy requirement . Parenteral drug product inspect visually particulate matter discoloration prior administration , whenever solution container permit . Dosing infant receive piperacillin-tazobactam per local standard care Once infant enrol study , steady state PK level may draw 4th , 5th , 6th dose piperacillin-tazobactam . These dos may include pre-study dos piperacillin-tazobactam post-consent , 'on-study ' , dose dosage dose interval piperacillin-tazobactam remains . If subject receive &lt; 4 dos on-study piperacillin-tazobactam time steady state PK sampling , ≥ 4 dos ( pre-study dos + study dos ) piperacillin-tazobactam record Study Drug Administration CRF . Other antimicrobial treatment Investigators encourage provide infant concomitant aminoglycoside therapy . Use antimicrobial agent ( vancomycin , antifungal ) may give per local standard care . A maximum 6 dos study piperacillin-tazobactam administer protocol . Additional dos piperacillin-tazobactam antimicrobial may administer per standard care record study CRFs . Procedures Visit Pre-Study Drug Administration Procedures ( Study Day 0 ) The following procedure complete prior administration study drug : . Review Inclusion/Exclusion Criteria prior infant enrollment b . Obtain sign date informed consent/HIPAA consent . c. Collect demographic data medical history d. Perform complete physical examination e. Obtain record infant weight medication dose weight calculation appropriate study drug dose different actual weight f. Record result hematology serum chemistry lab obtain within 72 hour prior enrollment accordance local standard care . Use laboratory value closest enrollment multiple test . 1 . Hematology labs include : hematocrit , hemoglobin , white blood cell count differential , platelet count . 2 . Serum chemistry include glucose , creatinine , blood urea nitrogen , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase , total direct bilirubin , sodium , potassium , chloride , calcium , magnesium , total protein , albumin . g. Record result sterile body fluid culture ( blood , urine , CSF , peritoneal fluid ) obtain standard clinical care 72 hour prior study drug administration . Record urine culture obtain sterile catheterization suprapubic aspiration . h. Document concomitant medication 72 hour prior study drug administration . Procedures During Study Drug Administration ( Study Days 1-2 ) . Record study drug time infusion PK sample obtain - include start/stop time infusion amount give b. Assess record AEs time first dose study drug . c. Assess record SAEs time first dose study drug . d. Record concomitant antimicrobial vasopressor administer e. Collect blood PK analysis ( Appendix 2 ) f. Record result clinical laboratory assessment obtain per local standard care one time daily study drug . 1 . Hematology assay include : hematocrit , hemoglobin , white blood cell count differential , platelet count . 2 . Serum chemistry include glucose , creatinine , blood urea nitrogen , aspartate transaminase ( AST ) , alanine transaminase ( ALT ) , alkaline phosphatase , total direct bilirubin , sodium , potassium , chloride , calcium , magnesium , total protein , albumin . g. Record result culture sterile body fluid ( blood , urine , CSF , peritoneal fluid , sterile body fluid ) obtain per standard care . Record urine culture obtain sterile catheterization suprapubic aspiration . Procedures follow Study Drug Administration 1 . Assess record adverse event ( AEs ) 72 hour follow last dose study drug 2 . Assess record serious adverse event ( SAEs ) 7 day follow last dose study drug Safety Adverse Events Reporting period AEs record time inform consent 72 hour follow last dose study drug non SAEs 7 day last dose study drug SAEs . Any AE occur time informed consent obtain initial dose study , consider related protocol specify procedure , must report . Procedures assess , record report AEs Throughout duration study , investigator closely monitor subject clinical evidence drug intolerance monitor clinically obtain laboratory value laboratory evidence AEs . AEs explain infant 's underlying illness occur course study report detail appropriate CRFs follow resolution becomes stable . All SAEs report study 's medical monitor within 24 hour . The description AE include description event , start date , stop date , intensity , serious , relationship study drug . The investigator must verify information . The Investigator responsible assess relationship study medication . Blood Volume PK Safety Laboratory Tests Blood sample volume minimize : Hematology chemistry laboratory measure record laboratory draw standard care draw strictly purpose study . A limited PK sample scheme employ total 0.8 mL blood ( 4 sample ) obtain subject PK analysis . Statistical Methods Definitions Populations Analysis All infant receive piperacillin-tazobactam analyze . These infant comprise population safety analysis , PK sample obtain , blood evaluate PK analysis . Demographics Descriptive statistic number observation , mean , median , 95 % confidence interval , standard deviation , standard error , minimum , maximum present group continuous variable ( age , weight , etc ) . Other descriptive statistic count , proportion , and/or percentage present dosage group summarize discrete variable ( race , sex , success rate , mortality rate , etc . ) The number infant complete , discontinue early study , reason discontinuation , summarize . Demographic baseline characteristic summarize group . Variables include race , age , sex , select clinical variable record prior initiation study drug . 7.4 Pharmacokinetics The follow PK parameter estimate : 1 . Systemic clearance ( CL ) 2 . Volume distribution ( Vd ) 3. maximum concentration ( Cmax ) , time maximum concentration ( Tmax ) , area curve ( AUC0-Τ ) , Ke half-life ( t1/2 ) 4 . CSF/plasma piperacillin-tazobactam concentration ratio 5 . Endotracheal aspirate/plasma piperacillin-tazobactam concentration ratio 6 . Saliva/plasma piperacillin-tazobactam concentration ratio 7 . Urine/plasma piperacillin-tazobactam concentration ratio The PK parameter MIC use estimate pharmacodynamic parameter exposure ( time MIC ) . Using sparse sample PK analysis , parameter ( clearance , Vd ) estimate follow cohort . The plasma concentrations-time profile piperacillin-tazobactam present tabular graphical form subject , age cohort , dosage level . The relationship plasma concentration and/or PK parameter demographic factor ( weight , gestational age , postnatal age ) , disease severity , toxicity co-administered medication investigate . Analysis potential relationship drug exposure subject result efficacy and/or safety response conduct . Sample Size The sample size design assess multiple dose PK piperacillin-tazobactam young infant . At least 4 infant enrol GA/PNA cohort . Infants enrolled ensure least 4 infant ≥3 evaluable PK sample enrol cohort .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Tazobactam</mesh_term>
	<mesh_term>Penicillanic Acid</mesh_term>
	<mesh_term>Piperacillin</mesh_term>
	<mesh_term>Piperacillin , tazobactam drug combination</mesh_term>
	<criteria>1 . Written permission parent legal guardian 2 . &lt; 61 day age 3 . Likely survive beyond first 48 hour enrollment 4 . Sufficient intravascular access ( either peripheral central ) receive study drug . AND ONE OF THE FOLLOWING 1 . Suspected systemic infection 2 . Receiving piperacillintazobactam part standard care 1 . History allergic reaction penicillin , cephalosporin , betalactamase inhibitor 2 . Urine output &lt; 0.5 mL/hr/kg prior 24 hour 3 . Serum creatinine &gt; 1.2 mg/dL 4 . Any condition would make subject caregiver , opinion investigator , unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>presume sepsis</keyword>
</DOC>